D. Krasnozhon

A randomized, double-blind phase II trial of exemestane plus MM-121 (a monoclonal antibody targeting ErbB3) or placebo in postmenopausal women with locally advanced or metastatic ER+/PR+, HER2-negative breast cancer.

G. MacBeath, P. Goss, V. Semiglazov, 2014 .

Transcutaneous oxegen measurement in the area of soft tissue radiation-induced fibrosis in patients with breast cancer

D. Romanovsky, A. A. Ovsyannikov, E. Topuzov, 2018, HERALD of North-Western State Medical University named after I.I. Mechnikov.

a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer

M. Buyse, K. Gelmon, J. Mackey, 2014 .

Double-blind, randomized, parallel group, phase III study to demonstrate equivalent efficacy and comparable safety of CT-P6 and trastuzumab, both in combination with paclitaxel, in patients with metastatic breast cancer (MBC) as first-line treatment.

Sudeep Gupta, Y. Im, A. Makhson, 2013 .

Primary results of ROSE/TRIO-12, a randomized placebo-controlled phase III trial evaluating the addition of ramucirumab to first-line docetaxel chemotherapy in metastatic breast cancer.

A. Manikhas, G. Konecny, V. Semiglazov, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.